MYND Life Sciences Signs Agreement to Acquire Rights for the Use of Psychedelics to Treat Alzheimer’s Disease and other Dementias Post published:October 27, 2021 Post category:Press Release
MYND Diagnostics Inc. Announces Participation in a Monash University (Australia) Proposal for $3 Million Clinical Trial Post published:October 13, 2021 Post category:Press Release
MYND Life Sciences Announces Diagnostic Division with Formation of Wholly-Owned Subsidiary – MYND Diagnostics Ltd. Post published:October 7, 2021 Post category:Press Release
MYND Life Sciences Announces Closing of Fully Subscribed $3 Million Convertible Debenture Unit Offering Post published:September 9, 2021 Post category:Press Release
MYND Life Sciences Announces $3 Million Convertible Debenture Unit Offering Post published:August 26, 2021 Post category:Press Release
MYND Life Sciences Announces DTC Eligibility Post published:August 11, 2021 Post category:Press Release
MYND Life Sciences Expands Intellectual Portfolio to Target Alzheimer’s disease and related forms of Dementia with Chemical Subclasses of Psilocybin Analogues Post published:June 23, 2021 Post category:Press Release
MYND Life Sciences Announces LOI with Eyam Vaccines and Immunotherapeutics Post published:June 17, 2021 Post category:Press Release
MYND Life Sciences Announces Patent Applications for Depression and Neuropsychiatric Disorder Drugs Post published:June 10, 2021 Post category:Press Release